Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12D”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05585320
What this trial is testing

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorPancreatic AdenocarcinomaMalignant Melanoma (Cutaneous)+1 more
Immuneering Corporation 209
Large-scale testing (Phase 3)Not Yet RecruitingNCT07262567
What this trial is testing

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc. 320
Early research (Phase 1)Looking for participantsNCT06447662
What this trial is testing

Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Who this might be right for
Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell Lung
Pfizer 330
Early research (Phase 1)Looking for participantsNCT06917079
What this trial is testing

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Who this might be right for
Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 387
Not applicableAvailableNCT07083479
What this trial is testing

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

Who this might be right for
Pancreatic Ductal AdenocarcinomaKRAS G12DKRAS G12V+12 more
Elicio Therapeutics
Testing effectiveness (Phase 2)Looking for participantsNCT06620848
What this trial is testing

HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.

Who this might be right for
Biliary Tract Cancer
Shanghai Zhongshan Hospital 49
Large-scale testing (Phase 3)Not Yet RecruitingNCT07232875
What this trial is testing

HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

Who this might be right for
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Jiangsu HengRui Medicine Co., Ltd. 588
Testing effectiveness (Phase 2)WithdrawnNCT06690281
What this trial is testing

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Who this might be right for
Gastrointestinal CarcinomaPancreatic CancerHepatocellular Cancer+5 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT05726864
What this trial is testing

ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaColorectal CancerKRAS G12D+11 more
Elicio Therapeutics 158
Testing effectiveness (Phase 2)Looking for participantsNCT06500676
What this trial is testing

GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Who this might be right for
KRAS G12D MutationsAdvanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc. 407
Testing effectiveness (Phase 2)Looking for participantsNCT07240766
What this trial is testing

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Who this might be right for
Borderline Resectable Pancreatic Adenocarcinoma
Zhejiang University 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06949761
What this trial is testing

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Who this might be right for
Solid Tumor
Qilu Pharmaceutical Co., Ltd. 240
Early research (Phase 1)Ended earlyNCT05737706
What this trial is testing

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Who this might be right for
Solid TumorAdvanced Solid TumorNon-small Cell Lung Cancer+2 more
Mirati Therapeutics Inc. 63
Early research (Phase 1)Looking for participantsNCT06403735
What this trial is testing

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

Who this might be right for
Non-small Cell Lung CancerColorectal CancerPancreatic Cancer+1 more
Qilu Pharmaceutical Co., Ltd. 250
Early research (Phase 1)Looking for participantsNCT06619587
What this trial is testing

Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Genentech, Inc. 410
Early research (Phase 1)Looking for participantsNCT06586515
What this trial is testing

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 630
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385678
What this trial is testing

HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 47
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Study completedNCT01833143
What this trial is testing

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 17
Early research (Phase 1)Not Yet RecruitingNCT07014878
What this trial is testing

DCTY1102 Injection in Patients With Advanced Solid Tumors

Who this might be right for
PDACCRC (Colorectal Cancer)NSCLC+1 more
Beijing DCTY Biotech Co.,Ltd. 110
Load More Results